Surgical excision of a feline orbital lacrimal gland adenocarcinoma with adjunctive cryotherapy and carboplatin‐impregnated bead implantation

The purpose of this report was to discuss the diagnosis, treatment, and outcome of a cat with an orbital lacrimal gland adenocarcinoma. A 14.5‐year‐old spayed female domestic shorthair cat was evaluated for a firm swelling at the left dorsotemporal orbital rim. The orbital mass was excised with preservation of the globe, and adjunctive cryotherapy was performed. A definitive diagnosis of lacrimal gland adenocarcinoma was obtained after histopathologic evaluation and histochemical staining with periodic acid–Schiff and mucicarmine. Thirteen months postoperatively, tumor regrowth occurred with a much larger osteolytic lesion, and a second surgery was performed consisting of tumor excision with implantation of carboplatin‐impregnated calcium sulfate hemihydrate beads. The cat has remained free of recurrence 11 months after the second surgery (26 months after initial diagnosis and surgery). A feline orbital lacrimal gland adenocarcinoma was successfully managed utilizing globe‐preserving surgical excision with adjunctive cryotherapy and subsequent carboplatin‐impregnated bead implantation. Orbital lacrimal gland adenocarcinoma in cats may not be as aggressive as other forms of periocular, head, and neck adenocarcinomas.     

Culture of human cardiac stem cells with improved cardiosphere-growing medium in vitro

AIM: To prepare an improved medium for culturing human cardiac stem cells. METHODS: The heart samples of the right auricle obtained from the patients after cardiac surgery were minced into pieces (about 1 mm×1 mm×1 mm), digested and cultured. The primary cells obtained were cultured with improved cardiosphere-growing medium (CGM) for proliferation, and the cells were identified by flow cytometry. Finally, purer c-kit+ cells were obtained by the method of magnetic bead sorting. RESULTS: After about 2 weeks of culture, small, round and phase-bright cells migrated from the well-adherent explants over a layer of fibroblast-like cells. These cells were collected by a brief digestion with Accutase, washed and cultured with improved CGM. No significant difference of the proliferative capacity between using traditional CGM and improved CGM was observed. After subculture and proliferation, the identification result by flow cytometry showed that the positive rate of c-Kit surface marker on these cells was (6.8±2.1)%. By the method of anti-c-Kit magnetic bead sorting, purer c-Kit+ cardiac stem cells were obtained and differentiated into cardiomyocytes. CONCLUSION: Purer c-Kit+ cardiac stem cells are isolated with the improved CGM culture.     

细纱松捻纱产生的机械原因

与细纱机工艺设计偏差所导致的松捻纱不同,机械零部件的使用及保养不当所产生的“松捻”纱,因其出现的随机性,更令设备管理者和操作者难于把握,而给紧随其后的加工工序造成不便及纱疵.因而详细分析“松捻”纱产生的原因,加强设备管理及保养,及时发现和消除“松捻”纱是细纱设备管理者与检修人员应具备的重要素质.     

Toxicity and efficacy of a novel doxorubicin and carboplatin chemotherapy protocol for the treatment of canine appendicular osteosarcoma following limb amputation

Objective To evaluate the safety and efficacy of a novel doxorubicin and carboplatin chemotherapy protocol for the treatment of dogs with appendicular osteosarcoma following limb amputation. Design Retrospective study. Procedure Dogs diagnosed with appendicular osteosarcoma, with no evidence of metastatic disease, treated with amputation and adjuvant chemotherapy consisting of two doses of doxorubicin given 14 days apart, followed by four doses of carboplatin at 3‐weekly intervals between September 2003 and December 2009 were identified from the medical records of Perth Veterinary Oncology. Haematological and gastrointestinal toxicities were assessed based on information in the medical records and recorded complete blood count results. The efficacy of the protocol was assessed by determining the median disease‐free interval (DFI) and overall survival time (OST) using the Kaplan‐Meier product‐limit method. Results In total, 33 dogs met the inclusion criteria. The median DFI was 231.5 days and the median OST was 247 days. With regard to haematological toxicity, 56% of dogs had a grade 1–2 neutropenia recorded as their highest marrow toxicity and 9% of dogs experienced a grade 3–4 neutropenia, all subsequent to doxorubicin administration. The highest gastrointestinal toxicity was grade 1–2 in 15 dogs (47%) and 5 dogs (16%) experienced grade 3–4 gastrointestinal toxicity. Conclusion This chemotherapy protocol did not result in a longer time to disease recurrence or OST in this population of dogs. Dual‐agent protocols have failed to improve survival times and therefore we conclude that a single‐agent protocol using carboplatin may be equally effective with less toxicity.     

Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder

Invasive transitional cell carcinoma (TCC) of the urinary bladder responds poorly to medical therapy. Combining platinum chemotherapy with a cyclooxygenase (cox) inhibitor has shown promise against canine TCC, where the disease closely mimics the human condition. A phase II clinical trial of carboplatin combined with the cox inhibitor, piroxicam, was performed in 31 dogs with naturally occurring, histopathologically confirmed, measurable TCC. Complete tumour staging was performed before and at 6‐week intervals during therapy. Tumour responses in 29 dogs included 11 partial remissions, 13 stable disease and five progressive disease. Two of the 31 dogs were withdrawn prior to the re‐staging of the tumour. Gastrointestinal toxicity was observed in 23 dogs. Hematologic toxicity was noted in 11 dogs. The median survival was 161 days from first carboplatin treatment to death. In conclusion, carboplatin/piroxicam induced remission in 40% of dogs providing evidence that a cox inhibitor enhances the antitumour activity of carboplatin. The frequent toxicity and limited survival, however, do not support the use of this specific protocol against TCC.     

Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis,sarcomatosis and mesothelioma,with or without malignant effusions: A retrospective analysis of 12 cases (1997–2002)*

Carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions, are difficult to treat and generally carry a poor prognosis. The purpose of this study was two‐fold; first, to determine the prognosis for dogs with carcinomatosis, sarcomatosis, or mesothelioma, with or without malignant effusions; second, to evaluate the safety and efficacy of treatment with intracavitary (IC) carboplatin and mitoxantrone in dogs with these syndromes. Nineteen dogs were evaluated. Seven were untreated and 12 were treated with IC chemotherapy (mitoxantrone and/or carboplatin), and multiple factors were analysed for significance with respect to survival time. The median survival time (MST) for untreated dogs was 25 days, whereas the MST for treated dogs was 332 days (Log Rank, P < 0.0001). Treatment with IC chemotherapy was well tolerated. This study suggests that IC chemotherapy with mitoxantrone and/or carboplatin is an effective treatment for dogs with carcinomatosis, sarcomatosis or mesothelioma, with or without malignant effusion.     

Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs

Transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) are standard treatments for advanced hepatocellular carcinoma (HCC) and particularly for unresectable tumors or liver metastases in humans. However, reports on TACE used in veterinary medicine are few. This study aimed to evaluate the feasibility and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE). We performed DEB-TACE in four clinically normal dogs and pharmacokinetically compared the results against hepatic arterial infusion (HAI) of cisplatin in two dogs. Drug-eluting beads (DEB) loaded with cisplatin were injected through a microcatheter for selective embolization of the left hepatic artery. After embolization, computed tomography (CT) images and histological examination findings were obtained during a 4-week observation period. Serum platinum concentrations were measured to evaluate cisplatin after each procedure. Biochemical analysis was performed during a 12-week observation period. Embolization was successful in all dogs, and there were no clinically apparent abnormalities. Embolization was confirmed up to 4 weeks after DEB-TACE in two of the four dogs and up to 1 week in the other two dogs using postoperative CT images. Cisplatin was not detected in peripheral veins in all dogs after DEB-TACE, but it was detected in trace amounts after HAI. DEB-TACE using cisplatin was safe and well tolerated by normal dogs. DEB-TACE may be useful in terms of determining systemic toxicity and drug concentration within tumors.     

双层浮球生物滤器设计及其水产养殖水处理性能试验

工厂化水产养殖水体的处钾主要包括增氧、分离（分离固体物和悬浮物）、生物过滤（降低BOD、氨氮和亚硝酸盐）、曝气（去除二氧化碳等）和杀菌消毒等处理过程。其中,悬浮物和氨氮去除是主要技术难点。自20世纪80年代,各国学者深入研究了固定滤床和流化滤床、喷淋滤床和浮球生物滤器（bead filter）等悬浮物和氨氮综合处理装置的性能。     

不同产地谷精珠中槲皮素含量的测定

[目的]测定不同产地谷精珠中槲皮素的含量,考察2种脱脂溶剂对谷精珠中槲皮素提取率的影响.[方法]采用2种溶剂脱脂处理,并用高效液相色谱-四通道紫外检测法测定不同产地谷精珠中槲皮素的含量.[结果]在5个产地中,石油醚脱脂后的谷精珠中槲皮素的含量分别为:301.4、597.77、622.36、582.56、453.51和406.06μg/g;其中,以浙江产的含量最高,海南产的最低.氯仿脱脂后的谷精珠中槲皮素的含量分别为:1057.56、953.43、916.16、809.17、738.28和627.32μ,g/g;其中,以海南产的含量最高,安徽产的最低.[结论]不同产地谷精珠中槲皮素含量差异较大;氯仿脱脂效果好,提取液中槲皮素的含量较高.